Nantahala Capital Management LLC purchased a new stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 852,700 shares of the company’s stock, valued at approximately $2,762,748. Nantahala Capital Management LLC owned 0.56% of Editas Medicine at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Captrust Financial Advisors purchased a new stake in Editas Medicine in the second quarter worth $26,000. Legal & General Group Plc purchased a new position in Editas Medicine during the second quarter valued at $31,000. StoneX Group Inc. purchased a new position in Editas Medicine during the fourth quarter valued at $33,000. Victory Capital Management Inc. bought a new stake in shares of Editas Medicine during the 3rd quarter valued at $36,000. Finally, Abel Hall LLC bought a new stake in shares of Editas Medicine during the 1st quarter valued at $36,000. Institutional investors own 71.90% of the company’s stock.
Trending Headlines about Editas Medicine
Here are the key news stories impacting Editas Medicine this week:
- Positive Sentiment: Zacks raised its 2026 EPS forecast to a loss of $0.90 from a loss of $1.25, while increasing its 2027 forecast to a loss of $1.16 from $1.35 and its 2028 forecast to a loss of $1.34 from $1.37. The revisions suggest analysts expect Editas Medicine’s losses to be narrower than previously projected.
- Positive Sentiment: Quarterly estimates were also improved, including Q3 2026 EPS to a loss of $0.25 from $0.34, Q4 2026 to a loss of $0.24 from $0.33, Q1 2027 to a loss of $0.28 from $0.34, and Q2 2027 to a loss of $0.29 from $0.34. Zacks also raised its Q3 2027, Q4 2027, Q1 2028 and Q2 2028 forecasts.
- Neutral Sentiment: Despite the revisions, Editas is still expected to report losses in every listed period. The current-year consensus remains a loss of $0.85 per share, and the company’s negative earnings and cash-burn profile leave the stock highly dependent on clinical, regulatory and partnership developments.
Editas Medicine Price Performance
Editas Medicine (NASDAQ:EDIT – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.12. Editas Medicine had a negative net margin of 157.32% and a negative return on equity of 196.63%. The firm had revenue of $11.89 million during the quarter, compared to analysts’ expectations of $2.85 million. On average, equities research analysts expect that Editas Medicine, Inc. will post -0.8 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
EDIT has been the subject of a number of analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Editas Medicine in a research note on Wednesday, May 27th. LADENBURG THALM/SH SH started coverage on Editas Medicine in a report on Tuesday, August 18th. They issued a “buy” rating and a $6.00 target price on the stock. Chardan Capital raised their price target on Editas Medicine from $3.50 to $4.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Weiss Ratings upgraded shares of Editas Medicine from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen raised shares of Editas Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $5.50.
View Our Latest Research Report on EDIT
Insider Transactions at Editas Medicine
In other news, CEO Gilmore Neil O’neill sold 15,380 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $2.70, for a total transaction of $41,526.00. Following the sale, the chief executive officer directly owned 248,313 shares of the company’s stock, valued at $670,445.10. This represents a 5.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 21,503 shares of company stock valued at $57,910. Insiders own 3.10% of the company’s stock.
Editas Medicine Profile
Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.
The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.
Featured Articles
- Five stocks we like better than Editas Medicine
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine, Inc. (NASDAQ:EDIT – Free Report).
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
